A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

This study is testing BL-M07D1, a new type of targeted drug called an antibody-drug conjugate (ADC), in people with HER2-positive or HER2-low metastatic breast cancer and other solid tumors. ADCs work like a guided missile — they attach to cancer cells and deliver chemotherapy directly to them. **You may be eligible if...** - You are 18–75 years old (or 18+ in later study phases) - You have advanced or metastatic HER2-positive or HER2-low breast cancer or another solid tumor - Your cancer has been confirmed by biopsy - Your cancer cannot be removed by surgery - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have untreated or active brain metastases - You have serious heart, liver, or lung problems - You have received certain prior treatments that overlap with this drug Talk to your doctor to see if this trial is right for you.